Printer Friendly

ROBERTS PHARMACEUTICAL CORPORATION COMPLETES ACQUISITION OF SMITHKLINE BEECHAM RESPIRATORY DRUG

ROBERTS PHARMACEUTICAL CORPORATION COMPLETES ACQUISITION OF SMITHKLINE
    BEECHAM RESPIRATORY DRUG
    EATONTOWN, N.J., Sept. 30 /PRNewswire/ -- Roberts Pharmaceutical Corporation (NASDAQ: RPCX) announced today that it has completed the acquisition of NUCOFED from SmithKline Beecham.
    Under the agreement, Roberts will have exclusive U.S. rights to NUCOFED, an established line of respiratory prescription products with annual sales in excess of $4 million in 1991.
    NUCOFED(R) is indicated for symptomatic relief when coughing and congestion are associated with upper respiratory infections and related conditions such as the common cold, bronchitis, influenza and sinusitis. The NUCOFED line consists of four dosage forms including pediatric and expectorant syrups.
    The transaction was completed on a cash basis.  Other terms of the agreement were not disclosed.
    Robert A. Vukovich, Roberts chairman and CEO, said, "The NUCOFED line of products provides and excellent strategic fit with our current CHERACOL(R) cough/cold product line.  This combination of products will enhance our overall performance in this important market sector.
    Roberts Pharmaceutical is an established pharmaceutical company specializing in prescription drug products which are currently marketed in seven countries with operating subsidiary companies in the United States, Canada, and the United Kingdom.  Roberts has seven drugs in late stage clinical development and currently markets over 80 different products for urological therapy, pain management, cough/cold, gastrointestinal disease, endocrine disorders and dermatological conditions.
    -0-             09/30/92
    CONTACT:  Anthony P. Maris of Roberts Pharmaceuticals, 908-389-1182
    (RPCX) CO:  ROBERTS PHARMACEUTICALS CORPORATION IN:  MTC ST:  NJ -- NY038 -- X450  09/30/92
COPYRIGHT 1992 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1992 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Date:Sep 30, 1992
Words:250
Previous Article:POLYCONOMICS, INC. FORMS NEW DIVISION; ZOAKOS NAMED DIRECTOR
Next Article:GENERAL DYNAMICS RECEIVES EPA AWARDS FOR INITIATIVES TO PROTECT OZONE LAYER
Topics:


Related Articles
ROBERTS PHARMACEUTICALS TO ACQUIRE MARKETED RESPIRATORY DRUG FROM SMITHKLINE BEECHAM
SMITHKLINE BEECHAM ACQUIRES CORSODYL FROM ICI
ROBERTS PHARMACEUTICAL ACQUIRES COMHIST ANTI-ALLERGY PRESCRIPTION PHARMACEUTICAL PRODUCT LINE FROM PROCTER & GAMBLE PHARMACEUTICALS
SMITHKLINE BEECHAM U.S. SELLS A-200 BRAND
SMITHKLINE BEECHAM PLC AND UNITED HEALTHCARE CORPORATION ANNOUNCE SB PURCHASE OF DIVERSIFIED PHARMACEUTICAL SERVICES, INC. AND FORMATION OF UNIQUE...
SMITHKLINE BEECHAM AND UNITED HEALTHCARE CORPORATION COMPLETE SB PURCHASE OF DIVERSIFIED PHARMACEUTICAL SERVICES, INC. AND FORMATION OF UNIQUE...
FTC URGED TO EXAMINE VERTICAL INTEGRATION ISSUES IN PRESCRIPTION DRUG MARKET PLACE
BLOCK DRUG COMPANY TO ACQUIRE NATURE'S REMEDY(R) FROM SMITHKLINE BEECHAM CONSUMER HEALTHCARE
Flamel Technologies S.A. Closes Acquisition of French Pharmaceutical Production Facility from SmithKline Beecham
Proposed Merger of Glaxo Wellcome and SmithKline Beecham Creating the Global Leader in Pharmaceuticals.

Terms of use | Copyright © 2017 Farlex, Inc. | Feedback | For webmasters